300206 Edan Instruments, Inc.
- 9.10
- -0.01-0.11%
Edan Instruments, Inc. News
edan instruments, inc. (300206.SZ): The company's molecular diagnostic platform has the ability to detect monkeypox virus.
On September 6th, edan instruments, inc. stated on the investor interactive platform that the company's molecular diagnostic platform has the ability to detect monkeypox virus, but it has not yet obtained registration and certification for this product domestically and internationally. The company will continue to monitor the market demand for monkeypox virus and changes in regulatory policies. If there is an increase in clinical demand in the future, and there is a feasible fast-track emergency approval registration channel, the company will timely proceed with the registration and certification of relevant products.
edan instruments, inc. (300206.SZ): Currently, the ECG monitoring products mainly serve medical institutions.
Edan Instruments, Inc. (300206.SZ) stated on the investor interaction platform that Edan does have a solid accumulation in the field of ECG monitoring technology and has established a comprehensive ECG diagnostic business system, including static ECG, exercise ECG, and ambulatory ECG/blood pressure monitoring, and also provides comprehensive ECG network solutions. Currently, the company's ECG monitoring products mainly serve medical institutions. Of course, the company also sees the huge potential of the home medical instruments market and considers this as one of the key directions for future development. Therefore, the company is actively deploying in this field and plans to adjust its business and product strategies according to market demand and
Edan Instruments, Inc. (300206.SZ): Currently, it does not involve the development of smart wristbands or watches.
Edan Instruments, Inc. (300206.SZ) stated on the investor interaction platform on September 6th that the company is currently not involved in the development of smart bracelets and watches. The products currently included in the company's personal health care business include fetal Doppler products, pelvic floor rehabilitation products, neonatal pulse oximeter products, finger pulse oximeter products, and thermometer products. In the field of home blood pressure monitoring, the company is about to launch the high cost-effective HP10 and HP11 series blood pressure monitors equipped with medical-grade blood pressure algorithm (China NMPA registration has been completed), which greatly reduces the user's discomfort with its fast results, accurate measurement, and medical-grade algorithm.
Edan Instruments, Inc. (300206.SZ): The company's target for blood gas consumables in 2024 is to ship over 10 million pieces.
On August 30, 2024, edan instruments, inc. (300206.SZ) held a performance briefing on the sales of blood gas consumables in the first half of the year and the annual expectations. The company stated that its target for blood gas consumables in 2024 is to ship over 10 million pieces. As of the first half of 2024, the shipment of blood gas consumables was about 4.5 million pieces. With the drive of inventory and incremental instruments in the second half of the year, the company is confident in achieving this annual target.
Libang Instruments: 2024 Semi-Annual Report Summary
Libang Instruments: 2024 Semi-Annual Report
Express News | Edan Instruments, Inc.: Net income in the first half of the year decreased by 39.59% year-on-year.
edan instruments, inc. (300206.SZ): net income of 0.125 billion yuan in the first half of the year, a year-on-year decrease of 39.59%.
Edan Instruments, Inc. (300206.SZ) announced on August 29th that in the first half of 2024, it achieved a total operating income of 0.922 billion yuan, a year-on-year decrease of 15.39%; net income attributable to the parent company's shareholders was 0.125 billion yuan, a year-on-year decrease of 39.59%; and the basic earnings per share was 0.2158 yuan.
Edan Instruments, Inc. (300206.SZ) released its half-year performance, with a net income of 0.125 billion yuan, a decrease of 39.59%.
Edan Instruments, Inc. (300206.SZ) released its half-yearly report for 2024, during the reporting period, the company achieved revenue...
The debut of the new high-end monitoring product, Lubang's full matrix digital transformation achievements are presented at China-Hospeq.
Shenzhen, August 14, 2024 / PRNewswire / - Recently, RuiBang's full range of digital solutions and multiple self-developed innovative core achievements once again appeared at the China International Medical Equipment Exhibition (China-Hospeq 2024) and technical exchange meeting to discuss global health and high-quality development. As a new force for high-quality development, RuiBang has accelerated the emergence of breakthrough digital innovation achievements, and provided a Chinese solution for global health and high-quality development with cutting-edge product ecology and strong innovation capabilities. Focused on...
Edan Instruments, Inc. (300206.SZ): Currently, microfluidic biochips are mainly used for the production of the company's own products.
On June 13th, Gelon Hui reported that an investor asked Edan Instruments Inc. (sz300206) on the interactive platform whether the company's microfluidic chip manufacturing base has personalized custom design and processing capabilities. The company replied that currently the company's microfluidic biochip is mainly used for the production of self-owned products to meet the business needs of Edan itself, and has not yet provided customized processing services to third parties.
Libang Instruments (300206.SZ) announced first-quarter results, net profit of 38.52 million yuan, a year-on-year decrease of 72.56%
Libang Instruments (300206.SZ) disclosed its report for the first quarter of 2024. The company achieved 4.4 revenue during the reporting period...
Libang Instruments (300206.SZ) plans to pay 2.07 yuan for 10 shares to be deducted from interest on May 6
Libang Instruments (300206.SZ) announced that the company plans to distribute cash shares for every 10 shares in the 2023 annual equity distribution...
Libang Instruments (300206.SZ): As of April 10, 2024, the number of shareholders of the company was 28,555
Gelonghui, April 18 | Libang Instruments (300206.SZ) said on the investor interactive platform that as of April 10, 2024, the number of shareholders of the company was 28,555.
“New” in terms of new quality productivity, Libang Digital Intelligence Chemical's new product CMEF was shocked by the release
SHENZHEN, April 14, 2024 /PRNewswire/ -- As the spring breeze blows past the Huangpu River, we know that the annual medical device event has begun again. In this vibrant time, the focus of the global medical community is once again on Shanghai, the Pearl of the Orient. Here, with 29 years of innovation and accumulation, Libang actively integrates into the overall development of the digital intelligence industry based on new quality productivity. With the theme of “wisdom • life”, Libang brought a new product launch ceremony to medical device colleagues and industry visitors. This is not only a demonstration of product innovation, but also a profound dialogue between technology and life. For exhibitors
Libang released its 2023 report: In vitro diagnosis revenue surged 19.79% year on year, and diversified businesses went hand in hand
SHENZHEN, March 30, 2024/PRNewswire/ -- On March 29, A-share listed company Libang Instruments (300206.SZ) disclosed its 2023 annual report. The report shows that in 2023, Libang achieved total revenue of 1,938 billion yuan, an increase of 11.22% over the previous year. The diversified business layout was continuously optimized to achieve steady operation and qualitative growth. Benefiting from product innovation, global localization, and improved organizational efficiency, Libang achieved year-on-year growth in domestic and international market revenue. In the domestic market, with the gradual growth of medical demand and the acceleration of domestic substitution, Libang relies on its technology and brand
Libang Instruments (300206.SZ): Net profit for 2023 will drop 5.00% to 221 million yuan, plan 10 to 2.07 yuan
On March 28, Ge Longhui (300206.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1,938 billion yuan, an increase of 11.22%; net profit attributable to shareholders of listed companies was 221 million yuan, down 5.00% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 194 million yuan, down 3.19% year on year; basic income per share was 0.3818 yuan; it plans to distribute a cash dividend of 2.07 yuan (tax included) to all shareholders for every 10 shares.
Express News | Libang Instruments and GH Labs sign licensing and commercialization agreement to break the “AI+ Pocket Ultrasound” game
Express News | Libang Instruments: Economical handheld ultrasound equipment driven by artificial intelligence is still in the joint development stage
EDAN Und GH Labs Arbeiten Gemeinsam an Der Entwicklung Von KI-gestützten Ultraschallgeräten
Analysis
Price Target
No Data
No Data